Cargando…

Potential diagnostic biomarkers for schizophrenia

Schizophrenia (SCH) is a complex and severe mental disorder with high prevalence, disability, mortality and carries a heavy disease burden, the lifetime prevalence of SCH is around 0.7%–1.0%, which has a profound impact on the individual and society. In the clinical practice of SCH, key problems suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Weihua, Huang, Hailiang, Duan, Jubao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388817/
https://www.ncbi.nlm.nih.gov/pubmed/37724326
http://dx.doi.org/10.1515/mr-2022-0009
_version_ 1785082204181757952
author Yue, Weihua
Huang, Hailiang
Duan, Jubao
author_facet Yue, Weihua
Huang, Hailiang
Duan, Jubao
author_sort Yue, Weihua
collection PubMed
description Schizophrenia (SCH) is a complex and severe mental disorder with high prevalence, disability, mortality and carries a heavy disease burden, the lifetime prevalence of SCH is around 0.7%–1.0%, which has a profound impact on the individual and society. In the clinical practice of SCH, key problems such as subjective diagnosis, experiential treatment, and poor overall prognosis are still challenging. In recent years, some exciting discoveries have been made in the research on objective biomarkers of SCH, mainly focusing on genetic susceptibility genes, metabolic indicators, immune indices, brain imaging, electrophysiological characteristics. This review aims to summarize the biomarkers that may be used for the prediction and diagnosis of SCH.
format Online
Article
Text
id pubmed-10388817
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-103888172023-09-18 Potential diagnostic biomarkers for schizophrenia Yue, Weihua Huang, Hailiang Duan, Jubao Med Rev (Berl) Review Schizophrenia (SCH) is a complex and severe mental disorder with high prevalence, disability, mortality and carries a heavy disease burden, the lifetime prevalence of SCH is around 0.7%–1.0%, which has a profound impact on the individual and society. In the clinical practice of SCH, key problems such as subjective diagnosis, experiential treatment, and poor overall prognosis are still challenging. In recent years, some exciting discoveries have been made in the research on objective biomarkers of SCH, mainly focusing on genetic susceptibility genes, metabolic indicators, immune indices, brain imaging, electrophysiological characteristics. This review aims to summarize the biomarkers that may be used for the prediction and diagnosis of SCH. De Gruyter 2022-08-02 /pmc/articles/PMC10388817/ /pubmed/37724326 http://dx.doi.org/10.1515/mr-2022-0009 Text en © 2022 the author(s), published by De Gruyter, Berlin/Boston https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Review
Yue, Weihua
Huang, Hailiang
Duan, Jubao
Potential diagnostic biomarkers for schizophrenia
title Potential diagnostic biomarkers for schizophrenia
title_full Potential diagnostic biomarkers for schizophrenia
title_fullStr Potential diagnostic biomarkers for schizophrenia
title_full_unstemmed Potential diagnostic biomarkers for schizophrenia
title_short Potential diagnostic biomarkers for schizophrenia
title_sort potential diagnostic biomarkers for schizophrenia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388817/
https://www.ncbi.nlm.nih.gov/pubmed/37724326
http://dx.doi.org/10.1515/mr-2022-0009
work_keys_str_mv AT yueweihua potentialdiagnosticbiomarkersforschizophrenia
AT huanghailiang potentialdiagnosticbiomarkersforschizophrenia
AT duanjubao potentialdiagnosticbiomarkersforschizophrenia